PHILIP O LIVINGSTON, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 107012
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(646) 227-3275
Personal information
See more information about PHILIP O LIVINGSTON at radaris.comName
Address
Phone
5431 Maple Beach Rd, Geneseo, NY 14454
4001 Luigi Ct, Schenectady, NY 12303
84 Lyman St, Brockport, NY 14420
40 Prospect Ave, Plattsburgh, NY 12901
156 E 79Th St APT 6C, New York, NY 10075
Organization information
See more information about PHILIP O LIVINGSTON at bizstanding.comPhilip O Livingston
235 W 56 St, New York, NY 10019
Industry:
Neurosurgeon, Family Doctor
Phone:
(646) 715-7241 (Phone)
Professional information
See more information about PHILIP O LIVINGSTON at trustoria.com
Fucosyl Gm1-Klh Conjugate Vaccine Against Small Cell Lung Cancer
Fucosyl Gm1-Klh Conjugate Vaccine Against Small Cell Lung Cancer
US Patent:
2003017, Sep 11, 2003
Filed:
Mar 24, 2000
Appl. No.:
09/534711
Inventors:
Philip Livingston - New York NY, US
International Classification:
A61K038/16, A61K039/00
US Classification:
514/008000, 514/012000
Abstract:
This invention provides for a composition comprising a fucosyl GM1 ganglioside or an oligosaccharide thereof conjugated to an immunogenic protein, an adjuvant, the amounts thereof being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier. This invention also provides a method of stimulating antibody production in a subject which comprises administering to the subject an effective amount of the above-described composition to stimulate antibody production. This invention also provides a method of enhancing antibody production in a subject which comprises administering to the subject an effective amount of the above-described composition to enhance antibody production. This invention also provides a method of preventing cancer in a subject which comprises administering to the subject an amount of the above-described composition effective to prevent cancer. This invention also provides a method of treating cancer in a subject which comprises administering to the subject an amount of the above-described composition effective to treat cancer.
Philip Ordway Livingston, New York NY
Philip Ordway Livingston, New York NY
Specialties:
Allergy & Immunology, Internal Medicine, Rheumatology, Medical Oncology, Clinical & Laboratory Immunology, Hematology & Oncology, Hematology, Hematology
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Education:
Harvard University(1969)
Triterpene Saponins, Methods Of Synthesis, And Uses Thereof
Triterpene Saponins, Methods Of Synthesis, And Uses Thereof
US Patent:
2013001, Jan 10, 2013
Filed:
Sep 13, 2012
Appl. No.:
13/613312
Inventors:
David Gin - Pelham NY, US
Michelle Adams - New York NY, US
Kai Deng - Guilderland NY, US
Nicholas Perl - New York NY, US
Annie Won - Groton NY, US
Philip Livingston - New York NY, US
Govind Ragupathi - New York NY, US
Michelle Adams - New York NY, US
Kai Deng - Guilderland NY, US
Nicholas Perl - New York NY, US
Annie Won - Groton NY, US
Philip Livingston - New York NY, US
Govind Ragupathi - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 39/39, C07H 23/00, A61P 37/04, C07H 15/18, C07C 61/29, C07H 15/256, A61K 39/00
US Classification:
4241841, 536 181, 536 172, 536 5, 4242781, 536119, 562498
Abstract:
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
Ganglioside-Klh Conjugate Vaccines Plus Os-21
Ganglioside-Klh Conjugate Vaccines Plus Os-21
US Patent:
7014856, Mar 21, 2006
Filed:
Jan 21, 1994
Appl. No.:
08/196154
Inventors:
Philip Ordway Livingston - New York NY, US
Friedhelm Helling - New York NY, US
Friedhelm Helling - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 39/385, A61K 39/39
US Classification:
4241941, 4241931, 42419511, 4242821, 4242771, 4242781, 4242801, 514 23, 514 25
Abstract:
This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
Glycoconjugates, Glycoamino Acids, Intermediates Thereto, And Uses Thereof
Glycoconjugates, Glycoamino Acids, Intermediates Thereto, And Uses Thereof
US Patent:
8623378, Jan 7, 2014
Filed:
Jan 31, 2011
Appl. No.:
13/018249
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US
Jennifer R. Allen - Indianapolis IN, US
Philip O. Livingston - New York NY, US
Lawrence Williams - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A01N 43/04, A61K 39/385, A61K 31/70, A61K 31/715
US Classification:
4241931, 4241941, 514 193, 514 23, 514 25, 514 42, 514 53, 514 54, 514 62, 530322, 5361231
Abstract:
The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.
Multivalent Glycopeptide Constructs And Uses Thereof
Multivalent Glycopeptide Constructs And Uses Thereof
US Patent:
2013009, Apr 18, 2013
Filed:
Jun 10, 2011
Appl. No.:
13/703563
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Govind Ragupathi - New York NY, US
Philip O. Livingston - New York NY, US
Jianglong Zhu - New York NY, US
Karthik Iyer - New York NY, US
Guangbin Yang - Forest Hills NY, US
Govind Ragupathi - New York NY, US
Philip O. Livingston - New York NY, US
Jianglong Zhu - New York NY, US
Karthik Iyer - New York NY, US
Guangbin Yang - Forest Hills NY, US
Assignee:
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
International Classification:
C07K 17/02, C07K 1/107
US Classification:
424450, 4241851, 530404, 530395, 530322
Abstract:
Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.
Colon Cancer Kh-1 And N3 Antigens
Colon Cancer Kh-1 And N3 Antigens
US Patent:
2002000, Jan 17, 2002
Filed:
Apr 12, 2001
Appl. No.:
09/833327
Inventors:
Samuel Danishefsky - Englewood NJ, US
Prashant Deshpande - Plaindome NJ, US
In Jong Kim - Seoul, KR
Philip Livingston - New York NY, US
Hyun Jin Kim - New York NY, US
Tae Kyo Park - Taejon, KR
Prashant Deshpande - Plaindome NJ, US
In Jong Kim - Seoul, KR
Philip Livingston - New York NY, US
Hyun Jin Kim - New York NY, US
Tae Kyo Park - Taejon, KR
International Classification:
A61K038/16, A61K031/726
US Classification:
514/008000, 536/053000, 514/054000, 530/322000, 530/395000
Abstract:
The present invention provides processes for the preparation of the KH-1 and N3 antigens, as well as related analgoues thereof, which are useful as anticancer therapeutics. The present invention also provides various intermediates useful in the preparation of KH-1 and N3 and analogues thereof. Additionally, the invention provides various compositions comprising any of the analogues of KH-1 and N3 available through the methods of the invention and pharmaceutical carriers useful in the treatment of subjects suffering from various forms of epithelial cancer.
Α-O-Linked Glycoconjugates, Methods Of Preparation And Uses Thereof
Α-O-Linked Glycoconjugates, Methods Of Preparation And Uses Thereof
US Patent:
7160856, Jan 9, 2007
Filed:
Jul 25, 2002
Appl. No.:
10/205021
Inventors:
Samuel J. Danishefsky - Englewood NJ, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Xiao Tao Chen - Newark DE, US
Jacob B. Schwarz - Ann Arbor MI, US
Peter Glunz - Wilmington DE, US
Philip O. Livingston - New York NY, US
Scott Kuduk - Harleyville PA, US
Lawrence Williams - New York NY, US
Dalibor Sames - New York NY, US
Samuel Hintermann - Basel, CH
Xiao Tao Chen - Newark DE, US
Jacob B. Schwarz - Ann Arbor MI, US
Peter Glunz - Wilmington DE, US
Philip O. Livingston - New York NY, US
Scott Kuduk - Harleyville PA, US
Lawrence Williams - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 38/14, A61K 39/385, C07K 9/00
US Classification:
514 8, 4241851, 4241941, 4242771, 530322
Abstract:
The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the α-O-linked glycoconjugates.
Colon Cancer Kh-1 And N3 Antigens
Colon Cancer Kh-1 And N3 Antigens
US Patent:
6238668, May 29, 2001
Filed:
Jan 13, 1998
Appl. No.:
9/042280
Inventors:
Samuel J. Danishefsky - Englewood NJ
Prashant P. Deshpande - Plaindome NJ
In Jong Kim - Seoul, KR
Philip Livingston - New York NY
Hyun Jin Kim - New York NY
Ragupathi Govindaswami - New York NY
Tae Kyo Park - Taejon, KR
Prashant P. Deshpande - Plaindome NJ
In Jong Kim - Seoul, KR
Philip Livingston - New York NY
Hyun Jin Kim - New York NY
Ragupathi Govindaswami - New York NY
Tae Kyo Park - Taejon, KR
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3900, A61K 39385, A61K 4500
US Classification:
4241841
Abstract:
The present invention provides processes for the preparation of the KH-1 and N3 antigens, as well as related analgoues thereof, which are useful as anticancer therapeutics. The present invention also provides various intermediates useful in the preparation of KH-1 and N3 and analogues thereof. Additionally, the invention provides various compositions comprising any of the analogues of KH-1 and N3 available through the methods of the invention and pharmaceutical carriers useful in the treatment of subjects suffering from various forms of epithelial cancer.
Polyvalent Conjugate Vaccine For Cancer
Polyvalent Conjugate Vaccine For Cancer
US Patent:
7479266, Jan 20, 2009
Filed:
Jan 6, 2004
Appl. No.:
10/752945
Inventors:
Philip O. Livingston - New York NY, US
Samuel J. Danishefsky - Englewood NJ, US
Samuel J. Danishefsky - Englewood NJ, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 47/06, A61K 47/30, A61K 39/385
US Classification:
424 157, 4241931, 4242771
Abstract:
This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.